Mary-Alice Miller net worth and biography

Mary-Alice Miller Biography and Net Worth

Insider of Acrivon Therapeutics

Mary Miller is Chief Legal Officer at Acrivon Therapeutics, Inc. Mary has over 20 years of corporate legal experience, having served as a strategic, proactive, and collaborative senior executive at several companies. Previously, she was General Counsel of Butterfly Network, a medical device company that she helped take public through a SPAC transaction. Prior to Butterfly, Mary served as the Chief Risk Officer and General Counsel of Columbia Care Inc., one of the largest vertically integrated medical marijuana operators in the United States, where she oversaw all legal, regulatory and compliance aspects of the organization, including helping to take the company public on the Canadian NEO exchange. Mary also spent several years starting and scaling her own digital media company, which she sold to Purch Media in 2016. Mary spent the first 7 years of her legal career at the law firm Ropes & Gray. Mary was named one of Boston Business Journal’s 2012 40 Under 40 and Mass High Tech’s 2013 Women to Watch. She received her J.D. from Boston College Law School and B.A. from Boston College.

What is Mary-Alice Miller's net worth?: The estimated net worth of Mary-Alice Miller is at least $150.49 thousand as of August 18th, 2026. Ms. Miller owns 82,009 shares of Acrivon Therapeutics stock worth more than $150,487 as of September 18th. This net worth approximation does not reflect any other assets that Ms. Miller may own. Learn More about Mary-Alice Miller's net worth.
How do I contact Mary-Alice Miller?: The corporate mailing address for Ms. Miller and other Acrivon Therapeutics executives is 480 Arsenal Way, Suite 100, Watertown, MA, 02472. Acrivon Therapeutics can also be reached via phone at 617-207-8979 and via email at [email protected]. Learn More on Mary-Alice Miller's contact information.
Has Mary-Alice Miller been buying or selling shares of Acrivon Therapeutics?: During the past quarter, Mary-Alice Miller has sold $1,380.33 of Acrivon Therapeutics stock. Most recently, Mary-Alice Miller sold 185 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $2.01, for a transaction totalling $371.85. Following the completion of the sale, the insider now directly owns 82,009 shares of the company's stock, valued at $164,838.09. Learn More on Mary-Alice Miller's trading history.
Who are Acrivon Therapeutics' active insiders?: Acrivon Therapeutics' insider roster includes Peter Blume-Jensen (CEO), Eric Devroe (COO), Adam Levy (CFO), and Mary-Alice Miller (Insider). Learn More on Acrivon Therapeutics' active insiders.
Are insiders buying or selling shares of Acrivon Therapeutics?: In the last twelve months, Acrivon Therapeutics insiders bought shares 3 times. They purchased a total of 67,832 shares worth more than $114,534.40. In the last twelve months, insiders at the sold shares 7 times. They sold a total of 18,253 shares worth more than $38,850.00. The most recent insider tranaction occured on August, 25th when CEO Peter Blume-Jensen sold 14,036 shares worth more than $31,019.56. Insiders at Acrivon Therapeutics own 10.5% of the company. Learn More about insider trades at Acrivon Therapeutics.
Information on this page was last updated on 8/25/2026.

Mary-Alice Miller Insider Trading History at Acrivon Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/18/2026	Sell	185	$2.01	$371.85	82,009
7/21/2026	Sell	573	$1.76	$1,008.48	82,194

Mary-Alice Miller Buying and Selling Activity at Acrivon Therapeutics

Acrivon Therapeutics Company Overview

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Today's Range

Now: $1.87

$1.69

$1.90

50 Day Range

MA: $1.88

$1.43

$2.39

2 Week Range

Now: $1.87

$1.27

$3.56

Volume

366,860 shs

Average Volume

918,161 shs

Market Capitalization

$79.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92